Regulation of myeloperoxidase‐specific T cell responses during disease remission in antineutrophil cytoplasmic antibody–associated vasculitis: The role of Treg cells and tryptophan degradation
Objective T lymphocytes have been implicated in the pathogenesis of antineutrophil cytoplasmic antibody–associated vasculitis (AAV). Patients with myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA) experience relapses less frequently than those with proteinase 3 ANCA, suggesting greate...
Saved in:
Published in | Arthritis and rheumatism Vol. 62; no. 5; pp. 1539 - 1548 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.05.2010
Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objective
T lymphocytes have been implicated in the pathogenesis of antineutrophil cytoplasmic antibody–associated vasculitis (AAV). Patients with myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA) experience relapses less frequently than those with proteinase 3 ANCA, suggesting greater immune regulation. This study was undertaken to investigate MPO‐specific T cell reactivity during disease remission and the factors regulating their responsiveness.
Methods
MPO‐specific T cells were quantified by enzyme‐linked immunospot assay with additional Treg cell depletion or exogenous interleukin‐2. Serum tryptophan and its metabolites were measured. In vivo blockade of indoleamine 2,3‐dioxygenase (IDO) was performed, and its effect on MPO reactivity was assessed.
Results
During disease remission, MPO‐specific interferon‐γ–producing T cell frequencies were comparable with those found in healthy controls and significantly lower than those found in patients with acute disease. CD4+CD25+ regulatory cells did not play a role in maintaining these low MPO‐specific T cell frequencies, since depletion of Treg cells did not augment MPO‐specific responses, and FoxP3 levels were diminished in patients compared with controls. Treg cell function, however, was comparable in patients and controls, suggesting numerical rather than functional deficiency. We found diminished serum tryptophan levels and elevated levels of its metabolite kynurenine in patients with MPO AAV as compared with controls. To confirm the effect of tryptophan degradation on MPO responses in vivo, we inhibited degradation in MPO‐immunized WKY rats and found greater immune responsiveness to MPO and a tendency to more severe glomerulonephritis.
Conclusion
Our findings indicate that MPO‐specific T cell frequencies are regulated during disease remission in association with tryptophan degradation. The tryptophan regulatory pathway is induced during active disease and persists during disease remission. |
---|---|
AbstractList | Objective
T lymphocytes have been implicated in the pathogenesis of antineutrophil cytoplasmic antibody–associated vasculitis (AAV). Patients with myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA) experience relapses less frequently than those with proteinase 3 ANCA, suggesting greater immune regulation. This study was undertaken to investigate MPO‐specific T cell reactivity during disease remission and the factors regulating their responsiveness.
Methods
MPO‐specific T cells were quantified by enzyme‐linked immunospot assay with additional Treg cell depletion or exogenous interleukin‐2. Serum tryptophan and its metabolites were measured. In vivo blockade of indoleamine 2,3‐dioxygenase (IDO) was performed, and its effect on MPO reactivity was assessed.
Results
During disease remission, MPO‐specific interferon‐γ–producing T cell frequencies were comparable with those found in healthy controls and significantly lower than those found in patients with acute disease. CD4+CD25+ regulatory cells did not play a role in maintaining these low MPO‐specific T cell frequencies, since depletion of Treg cells did not augment MPO‐specific responses, and FoxP3 levels were diminished in patients compared with controls. Treg cell function, however, was comparable in patients and controls, suggesting numerical rather than functional deficiency. We found diminished serum tryptophan levels and elevated levels of its metabolite kynurenine in patients with MPO AAV as compared with controls. To confirm the effect of tryptophan degradation on MPO responses in vivo, we inhibited degradation in MPO‐immunized WKY rats and found greater immune responsiveness to MPO and a tendency to more severe glomerulonephritis.
Conclusion
Our findings indicate that MPO‐specific T cell frequencies are regulated during disease remission in association with tryptophan degradation. The tryptophan regulatory pathway is induced during active disease and persists during disease remission. T lymphocytes have been implicated in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Patients with myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA) experience relapses less frequently than those with proteinase 3 ANCA, suggesting greater immune regulation. This study was undertaken to investigate MPO-specific T cell reactivity during disease remission and the factors regulating their responsiveness. MPO-specific T cells were quantified by enzyme-linked immunospot assay with additional Treg cell depletion or exogenous interleukin-2. Serum tryptophan and its metabolites were measured. In vivo blockade of indoleamine 2,3-dioxygenase (IDO) was performed, and its effect on MPO reactivity was assessed. During disease remission, MPO-specific interferon-gamma-producing T cell frequencies were comparable with those found in healthy controls and significantly lower than those found in patients with acute disease. CD4+CD25+ regulatory cells did not play a role in maintaining these low MPO-specific T cell frequencies, since depletion of Treg cells did not augment MPO-specific responses, and FoxP3 levels were diminished in patients compared with controls. Treg cell function, however, was comparable in patients and controls, suggesting numerical rather than functional deficiency. We found diminished serum tryptophan levels and elevated levels of its metabolite kynurenine in patients with MPO AAV as compared with controls. To confirm the effect of tryptophan degradation on MPO responses in vivo, we inhibited degradation in MPO-immunized WKY rats and found greater immune responsiveness to MPO and a tendency to more severe glomerulonephritis. Our findings indicate that MPO-specific T cell frequencies are regulated during disease remission in association with tryptophan degradation. The tryptophan regulatory pathway is induced during active disease and persists during disease remission. Objective T lymphocytes have been implicated in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Patients with myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA) experience relapses less frequently than those with proteinase 3 ANCA, suggesting greater immune regulation. This study was undertaken to investigate MPO-specific T cell reactivity during disease remission and the factors regulating their responsiveness. Methods MPO-specific T cells were quantified by enzyme-linked immunospot assay with additional Treg cell depletion or exogenous interleukin-2. Serum tryptophan and its metabolites were measured. In vivo blockade of indoleamine 2,3-dioxygenase (IDO) was performed, and its effect on MPO reactivity was assessed. Results During disease remission, MPO-specific interferon-producing T cell frequencies were comparable with those found in healthy controls and significantly lower than those found in patients with acute disease. CD4+CD25+ regulatory cells did not play a role in maintaining these low MPO-specific T cell frequencies, since depletion of Treg cells did not augment MPO-specific responses, and FoxP3 levels were diminished in patients compared with controls. Treg cell function, however, was comparable in patients and controls, suggesting numerical rather than functional deficiency. We found diminished serum tryptophan levels and elevated levels of its metabolite kynurenine in patients with MPO AAV as compared with controls. To confirm the effect of tryptophan degradation on MPO responses in vivo, we inhibited degradation in MPO-immunized WKY rats and found greater immune responsiveness to MPO and a tendency to more severe glomerulonephritis. Conclusion Our findings indicate that MPO-specific T cell frequencies are regulated during disease remission in association with tryptophan degradation. The tryptophan regulatory pathway is induced during active disease and persists during disease remission. T lymphocytes have been implicated in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Patients with myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA) experience relapses less frequently than those with proteinase 3 ANCA, suggesting greater immune regulation. This study was undertaken to investigate MPO-specific T cell reactivity during disease remission and the factors regulating their responsiveness.OBJECTIVET lymphocytes have been implicated in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Patients with myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA) experience relapses less frequently than those with proteinase 3 ANCA, suggesting greater immune regulation. This study was undertaken to investigate MPO-specific T cell reactivity during disease remission and the factors regulating their responsiveness.MPO-specific T cells were quantified by enzyme-linked immunospot assay with additional Treg cell depletion or exogenous interleukin-2. Serum tryptophan and its metabolites were measured. In vivo blockade of indoleamine 2,3-dioxygenase (IDO) was performed, and its effect on MPO reactivity was assessed.METHODSMPO-specific T cells were quantified by enzyme-linked immunospot assay with additional Treg cell depletion or exogenous interleukin-2. Serum tryptophan and its metabolites were measured. In vivo blockade of indoleamine 2,3-dioxygenase (IDO) was performed, and its effect on MPO reactivity was assessed.During disease remission, MPO-specific interferon-gamma-producing T cell frequencies were comparable with those found in healthy controls and significantly lower than those found in patients with acute disease. CD4+CD25+ regulatory cells did not play a role in maintaining these low MPO-specific T cell frequencies, since depletion of Treg cells did not augment MPO-specific responses, and FoxP3 levels were diminished in patients compared with controls. Treg cell function, however, was comparable in patients and controls, suggesting numerical rather than functional deficiency. We found diminished serum tryptophan levels and elevated levels of its metabolite kynurenine in patients with MPO AAV as compared with controls. To confirm the effect of tryptophan degradation on MPO responses in vivo, we inhibited degradation in MPO-immunized WKY rats and found greater immune responsiveness to MPO and a tendency to more severe glomerulonephritis.RESULTSDuring disease remission, MPO-specific interferon-gamma-producing T cell frequencies were comparable with those found in healthy controls and significantly lower than those found in patients with acute disease. CD4+CD25+ regulatory cells did not play a role in maintaining these low MPO-specific T cell frequencies, since depletion of Treg cells did not augment MPO-specific responses, and FoxP3 levels were diminished in patients compared with controls. Treg cell function, however, was comparable in patients and controls, suggesting numerical rather than functional deficiency. We found diminished serum tryptophan levels and elevated levels of its metabolite kynurenine in patients with MPO AAV as compared with controls. To confirm the effect of tryptophan degradation on MPO responses in vivo, we inhibited degradation in MPO-immunized WKY rats and found greater immune responsiveness to MPO and a tendency to more severe glomerulonephritis.Our findings indicate that MPO-specific T cell frequencies are regulated during disease remission in association with tryptophan degradation. The tryptophan regulatory pathway is induced during active disease and persists during disease remission.CONCLUSIONOur findings indicate that MPO-specific T cell frequencies are regulated during disease remission in association with tryptophan degradation. The tryptophan regulatory pathway is induced during active disease and persists during disease remission. |
Author | Fuchs, Dietmar Pusey, Charles D. Seidel, Judith Anna Shukla, Deepa Keteepe‐Arachi, Tracey Chavele, Konstantia‐Maria Salama, Alan D. |
Author_xml | – sequence: 1 givenname: Konstantia‐Maria surname: Chavele fullname: Chavele, Konstantia‐Maria – sequence: 2 givenname: Deepa surname: Shukla fullname: Shukla, Deepa – sequence: 3 givenname: Tracey surname: Keteepe‐Arachi fullname: Keteepe‐Arachi, Tracey – sequence: 4 givenname: Judith Anna surname: Seidel fullname: Seidel, Judith Anna – sequence: 5 givenname: Dietmar surname: Fuchs fullname: Fuchs, Dietmar – sequence: 6 givenname: Charles D. surname: Pusey fullname: Pusey, Charles D. – sequence: 7 givenname: Alan D. surname: Salama fullname: Salama, Alan D. email: A.salama@imperial.ac.uk |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22795787$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20155828$$D View this record in MEDLINE/PubMed |
BookMark | eNqFksuKFTEQhoOMOBdd-AKSjYiLM5NLpy_uhsEbDAjDcd2kk-pzIjlJm-pWezePIPhKPsk8iTkXFQR1lYT6_r8qVXVKjkIMQMhjzs45Y-JCp_FcVAWT98gJV6JZMC75ETlhjBULqRp-TE4RP-SnkEo-IMeCcaVqUZ-Q7zewmrweXQw09nQzg48DpPjFWY1wd_sVBzCud4YuqQHvaQIcYkBAaqfkwopah5DRHNg4xK2PC1SH0QWYxhSHtfPUzGMcvMZN9tmGumjnu9tvGjEap0ew9JNGM3k3OnxBl-vsFj1sC1omWO0SYxZaOqZ5yFZrHaiFVdJ2V_lDcr_XHuHR4Twj71-9XF69WVy_e_326vJ6YWRdyoVtZC2KnhdNoUVvSjBNVXUdZ6qGvmZlX0FXdiVTus933vGy6mQnLNQlr2pm5Bl5tvcdUvw4AY5t_vK2OB0gTthWqlCKFXkQ_yWlFI0sZZ3JJwdy6jZg2yG5jU5z-3NEGXh6AHKLtO-TDsbhb05UjarqKnPP95xJETFB_wvhrN2uSZvXpN2tSWYv_mCNG3etHJN2_l-Kz87D_Hfr9vJmuVf8AFo91VY |
CODEN | ARHEAW |
CitedBy_id | crossref_primary_10_1038_srep06406 crossref_primary_10_1681_ASN_2011030304 crossref_primary_10_1038_nrneph_2017_112 crossref_primary_10_1073_pnas_1210147109 crossref_primary_10_1111_nep_12574 crossref_primary_10_1186_s40168_019_0753_z crossref_primary_10_1038_s41467_023_41328_0 crossref_primary_10_1053_j_ajkd_2013_05_009 crossref_primary_10_3389_fimmu_2022_844300 crossref_primary_10_1186_s13075_020_02234_8 crossref_primary_10_1097_BOR_0b013e32834d2d52 crossref_primary_10_1007_s43440_021_00329_w crossref_primary_10_1111_j_1440_1681_2010_05418_x crossref_primary_10_1016_j_jaut_2017_12_005 crossref_primary_10_1038_ki_2013_2 crossref_primary_10_1007_s12026_019_9068_1 crossref_primary_10_1111_j_1365_2249_2011_04362_x crossref_primary_10_1186_s12882_019_1319_9 crossref_primary_10_1002_iub_1092 crossref_primary_10_1007_s10067_011_1767_5 crossref_primary_10_1016_j_autrev_2017_12_002 crossref_primary_10_1016_j_autrev_2011_05_004 crossref_primary_10_1038_s41584_018_0145_y crossref_primary_10_1016_j_cellimm_2013_04_007 crossref_primary_10_1016_j_autrev_2023_103271 crossref_primary_10_1016_j_revmed_2021_11_002 crossref_primary_10_1093_ndt_gfz043 crossref_primary_10_1016_j_ejr_2022_07_005 crossref_primary_10_1016_j_kint_2019_05_012 crossref_primary_10_2215_CJN_07590714 crossref_primary_10_1681_ASN_2017040367 crossref_primary_10_3109_08916934_2010_528476 crossref_primary_10_3389_fimmu_2017_00102 crossref_primary_10_1097_BOR_0000000000000145 crossref_primary_10_1681_ASN_2013090924 crossref_primary_10_1097_MNH_0b013e3283456731 crossref_primary_10_1146_annurev_pathol_011811_132453 crossref_primary_10_1038_nrrheum_2010_158 crossref_primary_10_1016_j_berh_2018_10_002 crossref_primary_10_1093_ndt_gfx057 crossref_primary_10_1097_TP_0b013e3181f9256a crossref_primary_10_3389_fimmu_2014_00504 crossref_primary_10_1093_labmed_lmac084 crossref_primary_10_1016_j_molimm_2018_09_005 crossref_primary_10_3389_fendo_2022_806361 crossref_primary_10_3389_fimmu_2021_809325 crossref_primary_10_1093_rheumatology_keac163 crossref_primary_10_1097_MD_0000000000040827 crossref_primary_10_1016_j_semnephrol_2011_06_007 crossref_primary_10_1002_art_37959 |
Cites_doi | 10.2174/1389200024605082 10.1159/000126065 10.1136/ard.2008.094714 10.1097/MOT.0b013e3282f3df26 10.1172/JCI0215918 10.1097/01.ASN.0000042163.73539.D4 10.1182/blood-2005-03-0921 10.1681/ASN.V103499 10.2353/ajpath.2009.080458 10.1056/NEJMoa020286 10.1002/art.21773 10.1189/jlb.0104054 10.1093/ndt/gfh487 10.1002/art.22692 10.1126/science.281.5380.1191 10.4049/jimmunol.0803277 10.1096/fj.04-3228fje 10.1016/S0272-6386(12)80879-1 10.1111/j.1523-1755.2004.00632.x 10.1046/j.1523-1755.2003.00259.x 10.7326/0003-4819-147-9-200711060-00005 10.1080/09629350400003100 10.1002/art.10384 10.1046/j.1365-2249.1996.d01-629.x 10.1111/j.1365-2249.2005.02808.x 10.1038/ki.1993.390 10.1093/clinchem/43.12.2424 10.1016/S1081-1206(10)61400-7 10.1016/S0272-6386(03)00025-8 10.1172/JCI34823 10.1136/ard.58.4.237 10.1016/j.molimm.2008.09.029 10.1111/j.1365-2249.2007.03365.x 10.4049/jimmunol.172.7.4100 10.1046/j.1365-2249.1998.00615.x |
ContentType | Journal Article |
Copyright | Copyright © 2010 by the American College of Rheumatology 2015 INIST-CNRS |
Copyright_xml | – notice: Copyright © 2010 by the American College of Rheumatology – notice: 2015 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 7T5 H94 |
DOI | 10.1002/art.27403 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Immunology Abstracts AIDS and Cancer Research Abstracts |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts |
DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1529-0131 |
EndPage | 1548 |
ExternalDocumentID | 20155828 22795787 10_1002_art_27403 ART27403 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: National Institute for Health Research (UK) Biomedical Research Centre Funding Scheme – fundername: National Institute for Health Research Clinician Scientist award – fundername: Vasculitis Foundation |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 10A 1CY 1KJ 1L6 1OB 1OC 1ZS 23N 24P 31~ 33P 3O- 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52W 52X 53G 5GY 5RE 66C 6J9 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAQQT AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFO ACMXC ACPOU ACRPL ACSCC ACXBN ACXQS ACYXJ ADBTR ADEOM ADIZJ ADMGS ADNMO ADOZA ADZCM ADZOD AEEZP AEIGN AEIMD AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AI. AIACR AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZFZN BDRZF BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM EBS EJD EMOBN EX3 F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J5H JPC KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES M65 MEWTI MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NNB OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q11 QB0 QRW RGB RIWAO RJQFR ROL RWI RX1 RXW RYL SAMSI SJN SUPJJ SV3 TAE TEORI TWZ UB1 V2E V8K V9Y VH1 W8V WH7 WIB WIH WIJ WIK WIN WJL WOW WQJ WRC WUP WXI WXSBR X6Y X7M XG1 XPP XV2 YFH YOC ZGI ZXP ZZTAW ~IA ~WT AAFWJ AAYXX AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 7X8 7T5 H94 |
ID | FETCH-LOGICAL-c3863-d93824f1494a2fc6ec977bb1058ef806f7eb6b605af6f71b167b3b2de861780c3 |
IEDL.DBID | DR2 |
ISSN | 0004-3591 1529-0131 |
IngestDate | Thu Jul 10 22:56:37 EDT 2025 Fri Jul 11 06:02:14 EDT 2025 Mon Jul 21 05:59:15 EDT 2025 Mon Jul 21 09:13:30 EDT 2025 Tue Jul 01 01:05:10 EDT 2025 Thu Apr 24 23:07:53 EDT 2025 Wed Jan 22 16:28:23 EST 2025 |
IsPeerReviewed | false |
IsScholarly | false |
Issue | 5 |
Keywords | Antineutrophil cytoplasmic antibody Enzyme Rheumatology Tryptophan Cardiovascular disease Vascular disease Vasculitis Peroxidases Immunological investigation T-Lymphocyte Remission Peroxidase Oxidoreductases |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3863-d93824f1494a2fc6ec977bb1058ef806f7eb6b605af6f71b167b3b2de861780c3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 20155828 |
PQID | 733293638 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_754550440 proquest_miscellaneous_733293638 pubmed_primary_20155828 pascalfrancis_primary_22795787 crossref_primary_10_1002_art_27403 crossref_citationtrail_10_1002_art_27403 wiley_primary_10_1002_art_27403_ART27403 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | May 2010 |
PublicationDateYYYYMMDD | 2010-05-01 |
PublicationDate_xml | – month: 05 year: 2010 text: May 2010 |
PublicationDecade | 2010 |
PublicationPlace | Hoboken |
PublicationPlace_xml | – name: Hoboken – name: Hoboken , NJ – name: United States |
PublicationTitle | Arthritis and rheumatism |
PublicationTitleAlternate | Arthritis Rheum |
PublicationYear | 2010 |
Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley |
Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley |
References | 2004; 65 2007; 147 2004; 22 2007; 148 1991; 18 1998; 281 2009; 68 2009; 46 2002; 110 1997; 43 2006; 54 1993; 44 1995; 13 2002; 13 2002; 3 2008; 13 2009; 174 2008; 146 1996; 103 1998; 112 2007; 56 2005; 19 2003; 349 2005; 141 2004; 93 2004; 19 2002; 46 2004; 172 2005; 106 1999; 58 2004; 13 2008; 118 1999; 10 2009; 183 2003; 41 2005; 77 2003; 64 e_1_2_7_5_2 Nassonov E (e_1_2_7_21_2) 1995; 13 e_1_2_7_4_2 e_1_2_7_3_2 e_1_2_7_2_2 e_1_2_7_8_2 e_1_2_7_7_2 e_1_2_7_6_2 e_1_2_7_19_2 e_1_2_7_18_2 e_1_2_7_17_2 e_1_2_7_16_2 e_1_2_7_15_2 e_1_2_7_14_2 e_1_2_7_13_2 e_1_2_7_12_2 Cunningham MA (e_1_2_7_9_2) 1999; 10 e_1_2_7_11_2 e_1_2_7_10_2 e_1_2_7_26_2 e_1_2_7_27_2 e_1_2_7_28_2 e_1_2_7_29_2 Sanders JS (e_1_2_7_25_2) 2004; 22 e_1_2_7_24_2 e_1_2_7_30_2 e_1_2_7_23_2 e_1_2_7_31_2 e_1_2_7_22_2 e_1_2_7_32_2 e_1_2_7_33_2 e_1_2_7_20_2 e_1_2_7_34_2 e_1_2_7_35_2 e_1_2_7_36_2 e_1_2_7_37_2 e_1_2_7_38_2 |
References_xml | – volume: 10 start-page: 499 year: 1999 end-page: 506 article-title: Prominence of cell‐mediated immunity effectors in “pauci‐immune” glomerulonephritis publication-title: J Am Soc Nephrol – volume: 13 start-page: 2983 year: 2002 end-page: 9 article-title: Reversibility with interleukin‐2 suggests that T cell anergy contributes to donor‐specific hyporesponsiveness in renal transplant patients publication-title: J Am Soc Nephrol – volume: 148 start-page: 419 year: 2007 end-page: 24 article-title: Tryptophan metabolism and indoleamine 2,3‐dioxygenase expression in coeliac disease publication-title: Clin Exp Immunol – volume: 349 start-page: 36 year: 2003 end-page: 44 article-title: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies publication-title: N Engl J Med – volume: 22 start-page: S94 issue: Suppl 36 year: 2004 end-page: 101 article-title: Risk factors for relapse in anti‐neutrophil cytoplasmic antibody (ANCA)‐associated vasculitis: tools for treatment decisions? publication-title: Clin Exp Rheumatol – volume: 112 start-page: 539 year: 1998 end-page: 46 article-title: T lymphocyte responses to anti‐neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA‐associated systemic vasculitis and persist during disease remission publication-title: Clin Exp Immunol – volume: 141 start-page: 201 year: 2005 end-page: 10 article-title: Off balance: T‐cells in antineutrophil cytoplasmic antibody (ANCA)‐associated vasculitides publication-title: Clin Exp Immunol – volume: 3 start-page: 175 year: 2002 end-page: 87 article-title: Neopterin as a marker for immune system activation publication-title: Curr Drug Metab – volume: 41 start-page: 776 year: 2003 end-page: 84 article-title: Outcome of ANCA‐associated renal vasculitis: a 5‐year retrospective study publication-title: Am J Kidney Dis – volume: 147 start-page: 611 year: 2007 end-page: 9 article-title: Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis publication-title: Ann Intern Med – volume: 19 start-page: 1347 year: 2005 end-page: 9 article-title: Indolamine 2,3‐dioxygenase is expressed in the CNS and down‐regulates autoimmune inflammation publication-title: FASEB J – volume: 43 start-page: 2424 year: 1997 end-page: 6 article-title: Simultaneous measurement of serum tryptophan and kynurenine by HPLC publication-title: Clin Chem – volume: 64 start-page: 1685 year: 2003 end-page: 94 article-title: Regulation by CD25+ lymphocytes of autoantigen‐specific T‐cell responses in Goodpasture's (anti‐GBM) disease publication-title: Kidney Int – volume: 13 start-page: 10 year: 2008 end-page: 5 article-title: Clinical relevance of indoleamine 2,3‐dioxygenase for alloimmunity and transplantation publication-title: Curr Opin Organ Transplant – volume: 18 start-page: 188 year: 1991 end-page: 95 article-title: The pathogenic role of antineutrophil cytoplasmic autoantibodies publication-title: Am J Kidney Dis – volume: 46 start-page: 1894 year: 2002 end-page: 904 article-title: In vitro cytokine production and proliferation of T cells from patients with anti–proteinase 3– and antimyeloperoxidase–associated vasculitis, in response to proteinase 3 and myeloperoxidase publication-title: Arthritis Rheum – volume: 183 start-page: 145 year: 2009 end-page: 54 article-title: Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4 CD25 Foxp3 T regulatory cells publication-title: J Immunol – volume: 44 start-page: 1366 year: 1993 end-page: 71 article-title: Free and protein‐bound tryptophan in serum of untreated patients with chronic renal failure publication-title: Kidney Int – volume: 54 start-page: 1619 year: 2006 end-page: 28 article-title: Mediation of endothelial cell damage by serine proteases, but not superoxide, released from antineutrophil cytoplasmic antibody–stimulated neutrophils publication-title: Arthritis Rheum – volume: 106 start-page: 2050 year: 2005 end-page: 8 article-title: Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte‐microvascular interactions in vivo publication-title: Blood – volume: 77 start-page: 33 year: 2005 end-page: 43 article-title: ANCA induces β integrin and CXC chemokine‐dependent neutrophil‐endothelial cell interactions that mimic those of highly cytokine‐activated endothelium publication-title: J Leukoc Biol – volume: 68 start-page: 1564 year: 2009 end-page: 71 article-title: Antimyeloperoxidase antibodies are a useful marker of disease activity in ANCA‐associated vasculitides publication-title: Ann Rheum Dis – volume: 118 start-page: 3431 year: 2008 end-page: 9 article-title: HIV‐activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3‐dioxygenase‐dependent mechanism publication-title: J Clin Invest – volume: 46 start-page: 999 year: 2009 end-page: 1006 article-title: IL‐2 signaling prevents T cell anergy by inhibiting the expression of anergy‐inducing genes publication-title: Mol Immunol – volume: 19 start-page: 2761 year: 2004 end-page: 8 article-title: Urinary monocyte chemoattractant protein‐1 (MCP‐1) is a marker of active renal vasculitis publication-title: Nephrol Dial Transplant – volume: 65 start-page: 2145 year: 2004 end-page: 52 article-title: Immune complex deposits in ANCA‐associated crescentic glomerulonephritis: a study of 126 cases publication-title: Kidney Int – volume: 58 start-page: 237 year: 1999 end-page: 45 article-title: Monocyte activation in patients with Wegener's granulomatosis publication-title: Ann Rheum Dis – volume: 110 start-page: 955 year: 2002 end-page: 63 article-title: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice publication-title: J Clin Invest – volume: 93 start-page: 398 year: 2004 end-page: 401 article-title: Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase‐antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement publication-title: Ann Allergy Asthma Immunol – volume: 174 start-page: 1212 year: 2009 end-page: 20 article-title: Experimental autoimmune vasculitis: an animal model of anti‐neutrophil cytoplasmic autoantibody‐associated systemic vasculitis publication-title: Am J Pathol – volume: 146 start-page: 73 issue: Suppl 1 year: 2008 end-page: 6 article-title: Involvement of regulatory T cells in the pathogenesis of Churg‐Strauss syndrome publication-title: Int Arch Allergy Immunol – volume: 281 start-page: 1191 year: 1998 end-page: 3 article-title: Prevention of allogeneic fetal rejection by tryptophan catabolism publication-title: Science – volume: 103 start-page: 253 year: 1996 end-page: 8 article-title: T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis publication-title: Clin Exp Immunol – volume: 56 start-page: 2080 year: 2007 end-page: 91 article-title: Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission publication-title: Arthritis Rheum – volume: 172 start-page: 4100 year: 2004 end-page: 10 article-title: Ligation of B7‐1/B7‐2 by human CD4 T cells triggers indoleamine 2,3‐dioxygenase activity in dendritic cells publication-title: J Immunol – volume: 13 start-page: 353 year: 1995 end-page: 6 article-title: Serum neopterin concentrations in Wegener's granulomatosis correlate with vasculitis activity publication-title: Clin Exp Rheumatol – volume: 13 start-page: 275 year: 2004 end-page: 83 article-title: Circulating cytokine profile in anti‐neutrophilic cytoplasmatic autoantibody‐associated vasculitis: prediction of outcome? publication-title: Mediators Inflamm – ident: e_1_2_7_19_2 doi: 10.2174/1389200024605082 – ident: e_1_2_7_29_2 doi: 10.1159/000126065 – ident: e_1_2_7_26_2 doi: 10.1136/ard.2008.094714 – ident: e_1_2_7_33_2 doi: 10.1097/MOT.0b013e3282f3df26 – ident: e_1_2_7_3_2 doi: 10.1172/JCI0215918 – ident: e_1_2_7_17_2 doi: 10.1097/01.ASN.0000042163.73539.D4 – ident: e_1_2_7_4_2 doi: 10.1182/blood-2005-03-0921 – volume: 10 start-page: 499 year: 1999 ident: e_1_2_7_9_2 article-title: Prominence of cell‐mediated immunity effectors in “pauci‐immune” glomerulonephritis publication-title: J Am Soc Nephrol doi: 10.1681/ASN.V103499 – ident: e_1_2_7_22_2 doi: 10.2353/ajpath.2009.080458 – ident: e_1_2_7_27_2 doi: 10.1056/NEJMoa020286 – ident: e_1_2_7_6_2 doi: 10.1002/art.21773 – ident: e_1_2_7_7_2 doi: 10.1189/jlb.0104054 – ident: e_1_2_7_15_2 doi: 10.1093/ndt/gfh487 – ident: e_1_2_7_28_2 doi: 10.1002/art.22692 – ident: e_1_2_7_32_2 doi: 10.1126/science.281.5380.1191 – ident: e_1_2_7_37_2 doi: 10.4049/jimmunol.0803277 – ident: e_1_2_7_34_2 doi: 10.1096/fj.04-3228fje – ident: e_1_2_7_5_2 doi: 10.1016/S0272-6386(12)80879-1 – ident: e_1_2_7_8_2 doi: 10.1111/j.1523-1755.2004.00632.x – ident: e_1_2_7_16_2 doi: 10.1046/j.1523-1755.2003.00259.x – ident: e_1_2_7_24_2 doi: 10.7326/0003-4819-147-9-200711060-00005 – ident: e_1_2_7_31_2 doi: 10.1080/09629350400003100 – ident: e_1_2_7_12_2 doi: 10.1002/art.10384 – volume: 13 start-page: 353 year: 1995 ident: e_1_2_7_21_2 article-title: Serum neopterin concentrations in Wegener's granulomatosis correlate with vasculitis activity publication-title: Clin Exp Rheumatol – ident: e_1_2_7_10_2 doi: 10.1046/j.1365-2249.1996.d01-629.x – ident: e_1_2_7_13_2 doi: 10.1111/j.1365-2249.2005.02808.x – ident: e_1_2_7_20_2 doi: 10.1038/ki.1993.390 – volume: 22 start-page: S94 issue: 36 year: 2004 ident: e_1_2_7_25_2 article-title: Risk factors for relapse in anti‐neutrophil cytoplasmic antibody (ANCA)‐associated vasculitis: tools for treatment decisions? publication-title: Clin Exp Rheumatol – ident: e_1_2_7_18_2 doi: 10.1093/clinchem/43.12.2424 – ident: e_1_2_7_2_2 doi: 10.1016/S1081-1206(10)61400-7 – ident: e_1_2_7_23_2 doi: 10.1016/S0272-6386(03)00025-8 – ident: e_1_2_7_36_2 doi: 10.1172/JCI34823 – ident: e_1_2_7_14_2 doi: 10.1136/ard.58.4.237 – ident: e_1_2_7_30_2 doi: 10.1016/j.molimm.2008.09.029 – ident: e_1_2_7_35_2 doi: 10.1111/j.1365-2249.2007.03365.x – ident: e_1_2_7_38_2 doi: 10.4049/jimmunol.172.7.4100 – ident: e_1_2_7_11_2 doi: 10.1046/j.1365-2249.1998.00615.x |
SSID | ssj0002353 |
Score | 1.6271644 |
Snippet | Objective
T lymphocytes have been implicated in the pathogenesis of antineutrophil cytoplasmic antibody–associated vasculitis (AAV). Patients with... T lymphocytes have been implicated in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Patients with myeloperoxidase (MPO)... Objective T lymphocytes have been implicated in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Patients with... |
SourceID | proquest pubmed pascalfrancis crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1539 |
SubjectTerms | Acute Disease Adeno-associated virus Aged Antibodies, Antineutrophil Cytoplasmic - immunology Biological and medical sciences Biomarkers - blood Diseases of the osteoarticular system Enzyme-Linked Immunosorbent Assay Female Humans Immunosuppressive Agents - therapeutic use Kynurenine - blood Lymphocyte Count Male Medical sciences Middle Aged Neopterin - blood Peroxidase - metabolism Remission Induction Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis T-Lymphocytes, Regulatory - enzymology T-Lymphocytes, Regulatory - immunology Tryptophan - blood Vasculitis - drug therapy Vasculitis - immunology Vasculitis - metabolism |
Title | Regulation of myeloperoxidase‐specific T cell responses during disease remission in antineutrophil cytoplasmic antibody–associated vasculitis: The role of Treg cells and tryptophan degradation |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fart.27403 https://www.ncbi.nlm.nih.gov/pubmed/20155828 https://www.proquest.com/docview/733293638 https://www.proquest.com/docview/754550440 |
Volume | 62 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhh1IofT-2jyBKD714Y1my1m5PpTSEQnoIG8ihYPRslyS2sb2H7Sk_odC_1F-SX9IZy95lS1pKbwaPbD1G0jfSzDeEvDKw5QnnTJR7KSPBshzmnBVRrmSqZz7TrDcUjz7JwxPx8TQ93SFvx1iYwA-xPnDDmdGv1zjBlW73N6Sh0LNTMKl6pk_01UJAdLyhjkr4wECJJ_9pzkZWoTjZX5fc2otu1aqFbvEhn8V1gHMbv_Yb0MEd8nmsevA7OZsuOz01335jdfzPtt0ltwdgSt8FTbpHdlx5n9w4Gq7eH5CfxyFrPYwjrTy9WKGvkYPKLCxshFeX3zFmE_2O6JzibQBtgveta2kIhaTDXRC8AN3CQzq6KKnCTBVu2TVV_XVxTs2qq2oA9BfwHXylK7u6uvyhBiVylgbXWWRiekNBxym6R2KF5o370v-4hYKWds2qRs4EVVKLfBghddRDcnLwYf7-MBpSQESGZ5JHNudZIjyYcUIl3khnAK9qDaAwcz6LpceULhpMMuXhmWkmZ5rrxLoMQx9jwx-R3bIq3RNChdAzWPnzhAkjLE-0ZdKlHjn5hPGCTcjrURkKM_CjY5qO8yIwOycFjErRj8qEvFyL1oEU5DqhvS2NWksiZyOukxNCRxUroN-xh1TpqmVbzDgHFAYr419EUgxHFyKekMdBOzffRxgMhjQ0qNexP1exAJupf3j676LPyM3RgSJmz8lu1yzdC8Blnd7rJ-AvI6c63A |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIgES4l1YHsVCHLhkG8eON0FcEKJaoNtDtZV6QVH8ghVtEmWzh-XUn4DEX-KX9JcwEye7WlQQ4hYp48SPsf2NPfMNIS80bHnCWh2kTspAsCSFOWdEkOYyViOXKNYaipNDOT4WH07iky3yuo-F8fwQqwM3nBnteo0THA-k99asodC1Q7CpkOrzCmb0bg2qozV5VMQ7Dko8-49T1vMKhdHequjGbnSjyufQMc5ntLgMcm4i2HYL2r9FPvWV954nX4eLRg31t994Hf-3dbfJzQ6b0jdeme6QLVvcJVcn3e37PfLzyCeuh6GkpaNnS3Q3slCbmYG98OL8O4ZtousRnVK8EKC1d8C1c-qjIWl3HQQvQL3wnI7OCppjsgq7aOqy-jI7pXrZlBVg-jP4Dr5SpVlenP_IOz2yhnrvWSRjekVBzSl6SGKFprX93P54DgUNbeplhbQJeUENUmL47FH3yfH-u-nbcdBlgQg0TyQPTMqTSDiw5EQeOS2tBsiqFODCxLoklA6zuiiwynIHz0wxOVJcRcYmGP0Yar5DtouysA8JFUKNYPFPIya0MDxShkkbO6TlE9oJNiAve23IdEeRjpk6TjNP7hxlMCpZOyoD8nwlWnlekMuEdjdUaiWJtI24VA4I7XUsg37HHsoLWy7m2YhzAGKwOP5FJMaIdCHCAXng1XP9fUTCYEtDg1ol-3MVMzCb2odH_y76jFwbTycH2cH7w4-PyfXenyJkT8h2Uy_sU4BpjdptZ-Mvj_Q-9w |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIlVIiDdleRQLceCSbRw73gROiLIqj1ao2ko9IEXxC1a0SZTNHpZTfwISf4lf0l_CTJzsalFBiFukjBM_Ptsz9sw3hDzTsOUJa3WQOikDwZIU5pwRQZrLWI1colhrKB4cyv1j8e4kPtkgL_tYGM8PsTxww5nRrtc4wSvjdlekodCzQzCpkOnzipBhgpDeO1pxR0W8o6DEo_84ZT2tUBjtLouubUbXqnwG_eJ8QovLNM51BbbdgcY3yKe-7t7x5Otw3qih_vYbreN_Nu4mud5ppvSVh9ItsmGL22TroLt7v0N-Hvm09TCQtHT0bIHORhYqMzWwE16cf8egTXQ8ohOK1wG09u63dkZ9LCTtLoPgBYALT-notKA5pqqw86Yuqy_TU6oXTVmBRn8G38FXqjSLi_MfeYcia6j3nUUqphcUQE7RPxIrNKnt5_bHMyhoaFMvKiRNyAtqkBDD5466S47Hbyav94MuB0SgeSJ5YFKeRMKBHSfyyGlpNSisSoFWmFiXhNJhThcFNlnu4JkpJkeKq8jYBGMfQ83vkc2iLOx9QoVQI1j604gJLQyPlGHSxg5J-YR2gg3I8x4Mme4I0jFPx2nmqZ2jDEYla0dlQJ4uRSvPCnKZ0M4aopaSSNqIC-WA0B5iGfQ79lBe2HI-y0acgxoGS-NfRGKMRxciHJBtj87V91EPBksaGtRi7M9VzMBoah8e_LvoE7L1cW-cfXh7-P4hudo7U4TsEdls6rl9DDpao3baufgL2fE9rw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Regulation+of+myeloperoxidase-specific+T+cell+responses+during+disease+remission+in+antineutrophil+cytoplasmic+antibody-associated+vasculitis%3A+the+role+of+Treg+cells+and+tryptophan+degradation&rft.jtitle=Arthritis+and+rheumatism&rft.au=Chavele%2C+Konstantia-Maria&rft.au=Shukla%2C+Deepa&rft.au=Keteepe-Arachi%2C+Tracey&rft.au=Seidel%2C+Judith+Anna&rft.date=2010-05-01&rft.eissn=1529-0131&rft.volume=62&rft.issue=5&rft.spage=1539&rft_id=info:doi/10.1002%2Fart.27403&rft_id=info%3Apmid%2F20155828&rft.externalDocID=20155828 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0004-3591&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0004-3591&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0004-3591&client=summon |